Rinvoq's Approval and Use for Eczema
Rinvoq (upadacitinib), a JAK inhibitor from AbbVie, is FDA-approved for moderate-to-severe atopic dermatitis (eczema) in adults and children 12+ weighing at least 40 kg whose condition isn't controlled by topical treatments or when those aren't advisable.[1]
Key Clinical Trial Results
In three phase 3 trials (Measure Up 1, Measure Up 2, AD Up), 45 mg once daily for 16 weeks followed by 15 mg maintenance outperformed placebo:
- 36-45% of patients achieved clear or almost clear skin (IGA 0/1), vs. 8-13% on placebo.
- 59-70% reached 75% improvement in eczema area and severity (EASI 75), vs. 10-12% on placebo.
- 80-91% saw at least 50% improvement (EASI 50).[2][3]
Long-term data (52-104 weeks) showed sustained results: up to 80% EASI 75 with 15 mg maintenance, and 74% itch reduction.[2]
| Endpoint | Rinvoq 15/30 mg (Week 16) | Placebo (Week 16) |
|----------|----------------------------|-------------------|
| IGA 0/1 | 36-45% | 8-13% |
| EASI 75 | 59-70% | 10-12% |
| EASI 90 | 34-42% | 4-5% |
Real-world studies align, with 60-80% EASI 75 in U.S. patients after 3-12 months.[4]
How It Compares to Dupixent
Rinvoq showed similar or better skin clearance than Dupixent (dupilumab) in head-to-head trials (Heads Up): 71% vs. 61% EASI 75 at week 16; faster itch relief (36% vs. 22% nearly resolved at week 2).[5] Both reduce flares, but Rinvoq acts quicker via oral dosing vs. Dupixent's injections.
Response Speed and Long-Term Control
Itch relief starts within days (47% reduction by week 1); full skin improvement by week 2-4. Over 2+ years, 71% maintained EASI 75, preventing flares in 91%.[2] Relapse risk rises if stopped.
Who Responds Best
Highest rates in ages 12-64 with baseline EASI ≥16 or prior biologic failure. Less effective in severe hand/foot eczema alone.[2] About 30% need dose increase to 30 mg for optimal control.[3]
Common Side Effects and Safety Concerns
Upper respiratory infections (20%), acne (10%), herpes zoster (3-5%), headache. Black box warnings for serious infections, clots, heart issues, cancer risk—monitor closely, avoid in active infections.[1][6] Long-term data (4 years) shows no new risks, but higher shingles incidence vs. biologics.
Who Should Avoid It
Not for mild eczema or those with active TB, recent live vaccines, or high clot/heart risk. Pregnancy category unknown; use contraception.[1]
[1]: FDA Label for Rinvoq
[2]: NEJM: Measure Up 1/2 Trials
[3]: Lancet: AD Up
[4]: JAMA Dermatology Real-World Study
[5]: NEJM: Heads Up vs. Dupixent
[6]: Rinvoq Safety Profile